Affymetrix Announces 2015 Tumor Profiling Grant Award Recipients to Support Translational Cancer Research
August 11 2015 - 6:30AM
Business Wire
Affymetrix, Inc. (Nasdaq:AFFX) has announced three recipients of
the 2015 United States Affymetrix Tumor Profiling Grant Program.
The grant program, first launched in 2014, is designed to support
translational cancer researchers in the discovery and validation of
novel diagnostic, prognostic, and therapeutic biomarkers that may
address an unmet clinical need. The qualifying grant projects must
use a multi-omics, systems-based approach that analyzes data from
multiple molecular and cellular levels to identify robust cancer
biomarkers for future application in the clinic. The high level of
interest from scientists reflects a growing appreciation of the
value of multi-parametric profiling of tumor samples.
The 2015 recipients of the Affymetrix Tumor Profiling Grant
Program are:
Dr. Tamara Lotan, MD, Johns Hopkins School of Medicine,
Baltimore, MDMolecular profiling to distinguish aggressive from
indolent prostate cancer
Dr. Gayle Woloschak, PhD, Northwestern University, Chicago,
ILDetermination of biomarkers associated with cervical cancer
relapse following radiation or chemo-radiation therapy
Dr. Antonia Sepulveda, MD, PhD, Columbia University, New York
City, NYIntegrated analysis of genomic gene expression
alterations for early detection in pancreatic cancer
The recipients are awarded with products from Affymetrix to
investigate and combine analysis of at least two different analytes
– DNA, RNA, or protein – across 30 tumor samples. The discovery and
validation of biomarkers from these projects has the potential to
inform better treatment strategies and prognosis prediction,
improving overall patient outcome.
“During the second year of our grant program, we continue to see
the growing level of interest in using a multi-omics based approach
to more rapidly and confidently identify novel cancer biomarkers,”
says David Weber, Chief Commercial Officer at Affymetrix. “We are
eager to partner with the grant recipients and support their
project.”
Learn more about how Affymetrix’ portfolio of solutions for DNA,
RNA, protein, and cell analysis can power breakthroughs in cancer
research and help translate discoveries into treatments at
www.affymetrix.com
About Affymetrix
Affymetrix provides leadership and support, partnering with
customers in pharmaceutical, diagnostic, and biotechnology
companies, as well as leading academic, government, and non-profit
research institutes in their quest to use biology for a better
world. More than 2,300 microarray systems have been shipped around
the world and more than 94,000 peer-reviewed papers have been
published citing Affymetrix technologies. Affymetrix is
headquartered in Santa Clara, California, and has manufacturing
facilities in Cleveland, San Diego, Vienna, and Singapore.
Affymetrix has about 1,100 employees and maintains sales and
distribution operations worldwide. For more information about
Affymetrix, please visit www.affymetrix.com
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix and the Affymetrix logo
trademarks are the property of Affymetrix, Inc. All other
trademarks are the property of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150811005390/en/
AffymetrixMedia
Contact:Mindy Lee-Olsen, 408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor
Contact:Doug Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024